Beleaguered pharmaceutical company Emergent BioSolutions — which, early into the pandemic, threw out coronavirus vaccine doses manufactured in East Baltimore due to lapses in quality — is selling its last major plant in the city.

The Gaithersburg-based company, maker of the overdose reversal drug Narcan, announced plans on Thursday to sell its drug product facility in Baltimore’s Camden neighborhood to the Taiwanese company Bora Pharmaceuticals Co. Ltd. for about $30 million. The facility’s 350 employees are expected to join Bora as part of the transaction, according to a news release from the company.

The sale follows news last month that Emergent plans to shutter its manufacturing facilities in Rockville and Baltimore’s Bayview neighborhood, and lay off about 300 employees. In an announcement about the closures, Emergent CEO Joe Papa said the decision was part of a multiyear plan to stabilize the company, manage its debt and set it up for long-term success.

Selling the company’s Camden facility — where workers packaged drugs and other products for market — is also part of that plan, Papa said in Thursday’s news release.

“We are grateful to our dedicated colleagues who have embodied Emergent’s mission to protect and enhance life by delivering on our customers’ commitments,” he said. “We are working to ensure a smooth transition to Bora, especially for our Camden team and valued customers, over the coming weeks and months.”

The sale is expected to close in the third quarter of 2024, the news release says. Emergent’s remaining manufacturing facilities are based in Lansing, Michigan, and Winnipeg, Canada.

Emergent, which got its start making an anthrax vaccine for the U.S. government, was awarded $628 million by the Trump administration in June 2020 to produce vaccines developed by AstraZeneca and Johnson & Johnson, despite early warning signs that the facilities weren’t ready. Five years earlier, Emergent got $163 million in federal dollars to build the Bayview manufacturing plant and prepare it to produce vaccines for a possible future pandemic.

The company later lost the contract and with it about $180 million in revenue, following manufacturing problems at the Bayview plant that made national headlines and caused the Food and Drug Administration to ask the company to pause production. A congressional panel looking into what went wrong at the facility later found that the company had thrown out 525 million vaccine doses due to contamination, expiration or other problems — a number the company has disputed.

Before Thursday’s announcement, Emergent cut about 211 jobs at the Bayview facility and about 20 from the drug product plant in Rockville. Last year, the company laid off 132 employees and sold its 280-person travel health business to Bavarian Nordic.